company background image

Shanghai Fosun Pharmaceutical (Group) SHSE:600196 Stock Report

Last Price


Market Cap







25 Sep, 2022


Company Financials +

Shanghai Fosun Pharmaceutical (Group) Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Shanghai Fosun Pharmaceutical (Group)
Historical stock prices
Current Share PriceCN¥30.48
52 Week HighCN¥59.37
52 Week LowCN¥30.21
1 Month Change-25.53%
3 Month Change-29.64%
1 Year Change-46.83%
3 Year Change20.90%
5 Year Change-10.85%
Change since IPO1,101.56%

Recent News & Updates

Shareholder Returns

600196CN PharmaceuticalsCN Market

Return vs Industry: 600196 underperformed the CN Pharmaceuticals industry which returned -24.5% over the past year.

Return vs Market: 600196 underperformed the CN Market which returned -18.6% over the past year.

Price Volatility

Is 600196's price volatile compared to industry and market?
600196 volatility
600196 Average Weekly Movement6.3%
Pharmaceuticals Industry Average Movement4.7%
Market Average Movement5.8%
10% most volatile stocks in CN Market9.3%
10% least volatile stocks in CN Market3.7%

Stable Share Price: 600196 is not significantly more volatile than the rest of CN stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: 600196's weekly volatility (6%) has been stable over the past year.

About the Company

199436,604Yuqing Chen

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. develops, manufactures, and sells pharmaceutical products in Mainland China and internationally. It operates in five segments: Pharmaceutical Manufacturing, Medical Devices and Medical Diagnosis, Healthcare Service, Pharmaceutical Distribution and Retail, Other Business segments.

Shanghai Fosun Pharmaceutical (Group) Fundamentals Summary

How do Shanghai Fosun Pharmaceutical (Group)'s earnings and revenue compare to its market cap?
600196 fundamental statistics
Market CapCN¥73.97b
Earnings (TTM)CN¥3.80b
Revenue (TTM)CN¥43.39b


P/E Ratio


P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
600196 income statement (TTM)
Cost of RevenueCN¥23.62b
Gross ProfitCN¥19.77b
Other ExpensesCN¥15.97b

Last Reported Earnings

Jun 30, 2022

Next Earnings Date


Earnings per share (EPS)1.42
Gross Margin45.56%
Net Profit Margin8.76%
Debt/Equity Ratio62.3%

How did 600196 perform over the long term?

See historical performance and comparison



Current Dividend Yield


Payout Ratio
We’ve recently updated our valuation analysis.


Is 600196 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 4/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 600196?

Other financial metrics that can be useful for relative valuation.

600196 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2.3x
Enterprise Value/EBITDA20.6x
PEG Ratio1x

Price to Earnings Ratio vs Peers

How does 600196's PE Ratio compare to its peers?

600196 PE Ratio vs Peers
The above table shows the PE ratio for 600196 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average28.2x
000661 Changchun High-Tech Industries (Group)
000538 Yunnan Baiyao GroupLtd
002001 Zhejiang NHU
600085 Beijing Tongrentang
600196 Shanghai Fosun Pharmaceutical (Group)

Price-To-Earnings vs Peers: 600196 is good value based on its Price-To-Earnings Ratio (21.4x) compared to the peer average (28.2x).

Price to Earnings Ratio vs Industry

How does 600196's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?

Price-To-Earnings vs Industry: 600196 is good value based on its Price-To-Earnings Ratio (21.4x) compared to the CN Pharmaceuticals industry average (29.4x)

Price to Earnings Ratio vs Fair Ratio

What is 600196's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

600196 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio21.4x
Fair PE Ratio36.5x

Price-To-Earnings vs Fair Ratio: 600196 is good value based on its Price-To-Earnings Ratio (21.4x) compared to the estimated Fair Price-To-Earnings Ratio (36.5x).

Share Price vs Fair Value

What is the Fair Price of 600196 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 600196 (CN¥30.48) is trading below our estimate of fair value (CN¥37.75)

Significantly Below Fair Value: 600196 is trading below fair value, but not by a significant amount.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Future Growth

How is Shanghai Fosun Pharmaceutical (Group) forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

Future Growth Score


Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 600196's forecast earnings growth (22.1% per year) is above the savings rate (3.2%).

Earnings vs Market: 600196's earnings (22.1% per year) are forecast to grow slower than the CN market (25.8% per year).

High Growth Earnings: 600196's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 600196's revenue (10.9% per year) is forecast to grow slower than the CN market (18.2% per year).

High Growth Revenue: 600196's revenue (10.9% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 600196's Return on Equity is forecast to be low in 3 years time (13%).

Discover growth companies

Past Performance

How has Shanghai Fosun Pharmaceutical (Group) performed over the past 5 years?

Past Performance Score


Past Performance Score 1/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 600196 has a large one-off loss of CN¥3.2B impacting its June 30 2022 financial results.

Growing Profit Margin: 600196's current net profit margins (8.8%) are lower than last year (13.3%).

Past Earnings Growth Analysis

Earnings Trend: 600196's earnings have grown by 10.2% per year over the past 5 years.

Accelerating Growth: 600196's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 600196 had negative earnings growth (-14.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (6%).

Return on Equity

High ROE: 600196's Return on Equity (8.6%) is considered low.

Discover strong past performing companies

Financial Health

How is Shanghai Fosun Pharmaceutical (Group)'s financial position?

Financial Health Score


Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: 600196's short term assets (CN¥32.1B) exceed its short term liabilities (CN¥32.0B).

Long Term Liabilities: 600196's short term assets (CN¥32.1B) exceed its long term liabilities (CN¥19.1B).

Debt to Equity History and Analysis

Debt Level: 600196's net debt to equity ratio (31.6%) is considered satisfactory.

Reducing Debt: 600196's debt to equity ratio has increased from 56.6% to 62.3% over the past 5 years.

Debt Coverage: 600196's debt is not well covered by operating cash flow (13.7%).

Interest Coverage: 600196 earns more interest than it pays, so coverage of interest payments is not a concern.

Balance Sheet

Discover healthy companies


What is Shanghai Fosun Pharmaceutical (Group) current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 4/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage


Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: 600196's dividend (1.84%) is higher than the bottom 25% of dividend payers in the CN market (0.52%).

High Dividend: 600196's dividend (1.84%) is low compared to the top 25% of dividend payers in the CN market (2.1%).

Stability and Growth of Payments

Stable Dividend: 600196's dividends per share have been stable in the past 10 years.

Growing Dividend: 600196's dividend payments have increased over the past 10 years.

Earnings Payout to Shareholders

Earnings Coverage: With its reasonably low payout ratio (37.8%), 600196's dividend payments are well covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: 600196 is paying a dividend but the company has no free cash flows.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Yuqing Chen (47 yo)



Mr. Yuqing Chen serves as its Co-President at Shanghai Fosun Pharmaceutical (Group) Co., Ltd since October 29, 2020 and serves as Co-Chief Executive Officer from June 1, 2022. He served as Senior Vice Pres...

Leadership Team

Experienced Management: 600196's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.

Board Members

Experienced Board: 600196's board of directors are considered experienced (3.3 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: 600196 insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

SHSE:600196 Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
08 Sep 22BuyCN¥441,250Xiaohui GuanIndividual12,500CN¥35.30
08 Sep 22BuyCN¥170,300Deyong WenIndividual5,000CN¥34.06
07 Sep 22BuyCN¥887,400Yifang WuIndividual25,000CN¥35.50
07 Sep 22BuyCN¥1,063,500Kexin WangIndividual30,000CN¥35.45
07 Sep 22BuyCN¥533,550Deyong WenIndividual15,000CN¥35.57

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.2%.

Top Shareholders

Top 25 shareholders own 46.23% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
Fosun International Holdings Ltd.
1,015,628,790CN¥31.0b0%no data
BlackRock, Inc.
38,973,647CN¥1.2b12.98%no data
China Securities Finance Corp, Asset Management Arm
Central Huijin Asset Management Ltd.
UBS Asset Management
Schroder Investment Management (Hong Kong) Limited
Bank Negara Malaysia
8,766,765CN¥267.2m0%no data
National Council for Social Security Fund
Franklin Resources, Inc.
China Asset Management Co., Ltd.
E Fund Management Co., Ltd.
China Universal Asset Management Company Ltd.
CITIC Securities Company Limited, Asset Management Arm
Fullgoal Fund Management Co., Ltd.
Yinhua Fund Management Co. Ltd.
Tianhong Asset Management Co., Ltd.
GF Fund Management Co., Ltd.
Dimensional Fund Advisors LP
3,094,619CN¥94.3m-8.4%no data
Nomura Asset Management Co., Ltd.
2,547,500CN¥77.6m0%no data
Geode Capital Management, LLC
2,431,446CN¥74.1m6.85%no data
Hua An Fund Management Co., Ltd.
JPMorgan Chase & Co, Brokerage and Securities Investments
Hwabao WP Fund Management Co., Ltd
Pacific Investment Management Company LLC
Caisse de dépôt et placement du Québec

Company Information

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.'s employee growth, exchange listings and data sources

Key Information

  • Name: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
  • Ticker: 600196
  • Exchange: SHSE
  • Founded: 1994
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: CN¥73.970b
  • Shares outstanding: 2.67b
  • Website:

Number of Employees


  • Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
  • Building A
  • No. 1289 Yishan Road
  • Shanghai
  • 200233
  • China


TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
600196SHSE (Shanghai Stock Exchange)YesDomestic SharesCNCNYAug 1998
600196XSSC (Shanghai Stock Exchange - Shanghai - Hong Kong Stock Connect)YesDomestic SharesCNCNYAug 1998
2196SEHK (The Stock Exchange of Hong Kong Ltd.)Foreign Shares-Foreign ListedHKHKDOct 2012
SFOS.FOTCPK (Pink Sheets LLC)Foreign Shares-Foreign ListedUSUSDOct 2012
08HHBST (Boerse-Stuttgart)Foreign Shares-Foreign ListedDEEUROct 2012
2196SHSC (Stock Exchange of Hong Kong Limited - Shanghai - Hong Kong Stock Connect)Foreign Shares-Foreign ListedHKHKDOct 2012
2196SZSC (The Stock Exchange of Hong Kong - Shenzhen - Hong Kong Stock Connect)Foreign Shares-Foreign ListedHKHKDOct 2012
08HHDB (Deutsche Boerse AG)Foreign Shares-Foreign ListedDEEUROct 2012

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/09/25 00:00
End of Day Share Price2022/09/23 00:00
Annual Earnings2021/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.